Urology department MRI use for Prostate Cancer Diagnosis

The request was successful.

Dear Cwm Taf Morgannwg University Health Board,
Prostate Cancer UK undertook a Freedom of Information Act (FOI) request of all Trusts, Health Boards and Health and Social Care Trusts in 2016, and again in 2018, with the aim of achieving a state of the nation overview of the use of mpMRI before biopsy.

We gained an in-depth understanding of the current status of mpMRI before prostate biopsy across the UK. We have used the data to make the case to National Commissioners for implementation support. It has also guided our funding and development of resources that respond to some of the challenges and barriers to implementation that centres told us they faced.

This third and final round of questions is our means of understanding what progress has been made and to identify where we can target our resources and National Commissioners’ support to have maximum impact.

We really appreciate your help with this. Please pass the below on to your urology department for them to complete. If this is not possible we would really appreciate your help to provide as much information as you can.

Yours faithfully,

Lizzie Ellis
1. Do you routinely conduct prostate MRI (bpMRI/mpMRI) scans before first prostate biopsy as part of the initial diagnostic process? (please tick all that apply):

a. Yes, using T2-weighted, diffusion-weighted (multi-b ADC and high/long b) and dynamic contrast enhanced (DCE) sequences
b. Yes, using T2-weighted, diffusion-weighted (multi-b ADC and high/long b) sequences but not DCE
c. No but we refer to another provider (please provide details)
d. No (please provide details)

2. If yes, to 1a: What percentage of men with suspected prostate cancer receive mpMRI before biopsy as part of the initial diagnostic process?

3. If yes, to 1b: What percentage of men with suspected prostate cancer receive bpMRI before biopsy as part of the initial diagnostic process?

4. If you are based in Wales, we acknowledge that Health Boards have been developing pre-biopsy mpMRI implementation plans in recent months to bring their practice into line with NICE guideline [NG131], Prostate cancer: diagnosis and management.

Please provide details of when you expect the following to be implemented for all eligible people:
• multiparametric MRI offered as the first-line investigation for people with suspected clinically localised prostate cancer; and
• People whose Likert score is 3 or more to be offered multiparametric MRI-influenced prostate biopsy.

5. What are your eligibility criteria/exclusion criteria for prostate MRI? (please tick all that apply):
a. Age (please provide details)
b. Symptoms (please provide details)
c. Life expectancy (please provide details)
d. Contra-indications (please provide details)
e. Other (please provide details)

6. Are you using results from the prostate MRI before biopsy to rule some men out of biopsy as part of the initial diagnostic process? (yes/no)

7. Do you biopsy all PI-RADS or LIKERT 3 scores?
a. Yes
b. No
c. Dependent on patient histology

8. What threshold do you mostly use for ruling men out of biopsy?
a. PI-RADs 3 and above
b. LIKERT 3 and above
c. PI-RADs 4 and above
d. LIKERT 4 and above
e. Varies depending on age (Please provide detail)
f. Varies depending on other factors (Please provide detail)

9. What percentage of men do you estimate are ruled out of biopsy?

10. Have there been any changes to your prostate MRI capacity in the last year? (please choose all that apply):
a. An additional or new MRI scanner
b. Increased MRI scanner slots for prostate
c. Agreement to use Dynamic Contrast Enhancement
d. No longer using Dynamic Contrast Enhancement
e. A scanner/magnet upgrade
f. other (free text)

11. Has the number of radiologists at your trust/health board who report prostate MRI scans changed in the last year?
a. Increased
b. Decreased
c. Stayed the same

12. How many radiologists at your trust/health board report at least 250 prostate MRI scans per year?

13. Which of the following processes do you follow to manage men ruled out of an immediate biopsy, but with a raised PSA?
a. NICE Guidelines: prostate cancer diagnosis and management (NG131)
b. A local protocol (please provide details)
c. Other (please provide details)

Claire Northwell-Todd (CTUHB - Corporate Development), Cwm Taf Morgannwg University Health Board

3 Attachments

Dear Ms Ellis,

 

Freedom of Information Request:  Our Reference CTHB_275_19  

 

Thank you for your request for information.  We are currently processing
your request and will be in touch shortly.

 

We aim to provide you with a full response within 20 working days from
receipt of your request as required by the Freedom of Information Act.  If
this is not possible we will of course let you know.

 

In the meantime should you have any queries, please contact me, on 01443
744835 or [1][email address].

 

Kind regards

 

 

Julie Butler

Freedom of Information Officer / Swyddog Rhyddid Gwybodaeth

Corporate Development / Datblygu Corfforaethol

[2]IG Aware Signature

----------------------------------------------------------

Cwm Taf Morgannwg University Health Board / Bwrdd Iechyd Prifysgol Cwm Taf
Morgannwg

Headquarters - Pencadlys | Ynysmeurig House â TÅ· Ynysmeurig | Unit 3
Navigation Park

Uned 3 Parc Navigation

Abercynon

Rhondda Cynon Taf

CF45 4SN

----------------------------------------------------------

 

WHTN: 01800 24916

 

[3][email address]

 

 

 

 

A wnewch chi ystyried yr amgylchedd cyn argraffu r neges hon
Please consider the environment before printing this email

Dolen gyswllt at ymwadiad Bwrdd Iechyd Prifysgol Cwm Taf - [4]Ymwadiad
Link to Cwm Taf Health Board email disclaimer - [5]Disclaimer

Dilynwch ni ar Twitter [6]@CwmTaf / Dilynwch ni ar [7]Facebook
Follow us on Twitter [8]@CwmTaf / Follow us on [9]Facebook

*Cwm Taf Health Board is the operational name of Cwm Taf University Local
Health Board
*Bwrdd Iechyd Prifysgol Cwm Taf yw enw gweithredol Bwrdd Iechyd Lleol
Prifysgol Cwm Taf

References

Visible links
1. mailto:[email address]
3. mailto:[email address]
4. http://cwmtaf.wales/e-mail-disclaimer/
5. http://cwmtaf.wales/e-mail-disclaimer/
6. https://twitter.com/cwmtaf
7. https://www.facebook.com/cwmtaf
8. https://twitter.com/cwmtaf
9. https://www.facebook.com/cwmtaf

Julie Butler (CTUHB - Corporate Development), Cwm Taf Morgannwg University Health Board

2 Attachments

Dear Ms Ellis,

 

Freedom of Information Request: Our Reference CTHB_275_19

 

Further to your request for information, please see the response from Cwm
Taf Morgannwg University Health Board attached.

 

Please contact the Corporate Services Department if you have any queries.

 

Kind regards

 

Julie Butler

Freedom of Information Officer / Swyddog Rhyddid Gwybodaeth

Corporate Development / Datblygu Corfforaethol

 

----------------------------------------------------------

Cwm Taf Morgannwg University Health Board / Bwrdd Iechyd Prifysgol Cwm Taf
Morgannwg

Headquarters - Pencadlys | Ynysmeurig House â TÅ· Ynysmeurig | Unit 3
Navigation Park

Uned 3 Parc Navigation

Abercynon

Rhondda Cynon Taf

CF45 4SN

----------------------------------------------------------

phone / ffôn :  01443 744916

fax / ffacs    :  01443 744835

 

WHTN: 01800 24835

 

[1][email address]

 

 

A wnewch chi ystyried yr amgylchedd cyn argraffu r neges hon
Please consider the environment before printing this email

Dolen gyswllt at ymwadiad Bwrdd Iechyd Prifysgol Cwm Taf - [2]Ymwadiad
Link to Cwm Taf Health Board email disclaimer - [3]Disclaimer

Dilynwch ni ar Twitter [4]@CwmTaf / Dilynwch ni ar [5]Facebook
Follow us on Twitter [6]@CwmTaf / Follow us on [7]Facebook

*Cwm Taf Health Board is the operational name of Cwm Taf University Local
Health Board
*Bwrdd Iechyd Prifysgol Cwm Taf yw enw gweithredol Bwrdd Iechyd Lleol
Prifysgol Cwm Taf

References

Visible links
1. mailto:[email address]
2. http://cwmtaf.wales/e-mail-disclaimer/
3. http://cwmtaf.wales/e-mail-disclaimer/
4. https://twitter.com/cwmtaf
5. https://www.facebook.com/cwmtaf
6. https://twitter.com/cwmtaf
7. https://www.facebook.com/cwmtaf